These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 12954583)

  • 1. A phase II study of cisplatin, etoposide and gemcitabine in an unfavourable group of patients with carcinoma of unknown primary site.
    Balaña C; Manzano JL; Moreno I; Cirauqui B; Abad A; Font A; Mate JL; Rosell R
    Ann Oncol; 2003 Sep; 14(9):1425-9. PubMed ID: 12954583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carcinoma of unknown primary site: sequential treatment with paclitaxel/carboplatin/etoposide and gemcitabine/irinotecan: a Minnie Pearl Cancer Research Network phase II trial.
    Greco FA; Rodriguez GI; Shaffer DW; Hermann R; Litchy S; Yardley DA; Burris HA; Morrissey LH; Erland JB; Hainsworth JD
    Oncologist; 2004; 9(6):644-52. PubMed ID: 15561808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of gemcitabine in non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group. Provincial Systemic Treatment Disease Site Group.
    Evans WK; Kocha W; Gagliardi A; Eady A; Newman TE
    Cancer Prev Control; 1999 Feb; 3(1):84-94. PubMed ID: 10474757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of first-line chemotherapy with gemcitabine, etoposide, and cisplatin for patients with advanced urothelial carcinoma.
    Urakami S; Fujii Y; Yamamoto S; Yuasa T; Kitsukawa S; Sakura M; Yano A; Saito K; Masuda H; Yonese J; Fukui I
    Urol Oncol; 2014 Jan; 32(1):35.e1-7. PubMed ID: 23562233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized study of gemcitabine monotherapy versus etoposide/cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer.
    Manegold C; Drings P; von Pawel J; Ricci S; Dornoff W; van Walree N; ten Bokkel Huinink W; Chemaissani A; Stahel P; Bergman B; Wagenius G; Sederholm C; Mattson K; Liippo K; Kellokumpu-Lehtinen P
    Semin Oncol; 1997 Jun; 24(3 Suppl 8):S8-13-S8-17. PubMed ID: 9207310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer.
    Cardenal F; López-Cabrerizo MP; Antón A; Alberola V; Massuti B; Carrato A; Barneto I; Lomas M; García M; Lianes P; Montalar J; Vadell C; González-Larriba JL; Nguyen B; Artal A; Rosell R
    J Clin Oncol; 1999 Jan; 17(1):12-8. PubMed ID: 10458212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer.
    Manegold C; Bergman B; Chemaissani A; Dornoff W; Drings P; Kellokumpu-Lehtinen P; Liippo K; Mattson K; van Pawel J; Ricci S; Sederholm C; Stahel RA; Wagenius G; van Walree N; ten Bokkel-Huinink W
    Ann Oncol; 1997 Jun; 8(6):525-9. PubMed ID: 9261520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I/II trial of gemcitabine plus cisplatin and etoposide in patients with small-cell lung cancer.
    De Marinis F; Migliorino MR; Paoluzzi L; Portalone L; Ariganello O; Cortesi E; Gamucci T; Gasperoni S; Cipri A; Martelli O; Nelli F;
    Lung Cancer; 2003 Mar; 39(3):331-8. PubMed ID: 12609572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I/II study of a combined gemcitabine, etoposide, and cisplatin chemotherapy regimen for metastatic urothelial carcinoma.
    Tsukamoto T; Yonese J; Ohkubo Y; Fukui I
    Cancer; 2006 Jun; 106(11):2363-8. PubMed ID: 16649219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II, open-label trial of bortezomib (VELCADE(®)) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer.
    Kontopodis E; Kotsakis A; Kentepozidis N; Syrigos K; Ziras N; Moutsos M; Filippa G; Mala A; Vamvakas L; Mavroudis D; Georgoulias V; Agelaki S
    Cancer Chemother Pharmacol; 2016 May; 77(5):949-56. PubMed ID: 26994909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cisplatin alone or combined with gemcitabine in carcinomas of unknown primary: results of the randomised GEFCAPI 02 trial.
    Gross-Goupil M; Fourcade A; Blot E; Penel N; Négrier S; Culine S; Chaigneau L; Lesimple T; Priou F; Lortholary A; Kaminsky MC; Provencal J; Voog E; Bouzy J; Laplanche A; Fizazi K
    Eur J Cancer; 2012 Mar; 48(5):721-7. PubMed ID: 22317952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma.
    Philip PA; Zalupski MM; Vaitkevicius VK; Arlauskas P; Chaplen R; Heilbrun LK; Adsay V; Weaver D; Shields AF
    Cancer; 2001 Aug; 92(3):569-77. PubMed ID: 11505401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicentric phase II study of cisplatin and etoposide in patients with metastatic carcinoma of unknown primary.
    Voog E; Merrouche Y; Trillet-Lenoir V; Lasset C; Peaud PY; Rebattu P; Negrier S
    Am J Clin Oncol; 2000 Dec; 23(6):614-6. PubMed ID: 11202809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-agent gemcitabine: an active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer.
    ten Bokkel Huinink WW; Bergman B; Chemaissani A; Dornoff W; Drings P; Kellokumpu-Lehtinen PL; Liippo K; Mattson K; von Pawel J; Ricci S; Sederholm C; Stahel RA; Wagenius G; Walree NV; Manegold C
    Lung Cancer; 1999 Nov; 26(2):85-94. PubMed ID: 10568679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study.
    Perng RP; Chen YM; Ming-Liu J; Tsai CM; Lin WC; Yang KY; Whang-Peng J
    J Clin Oncol; 1997 May; 15(5):2097-102. PubMed ID: 9164223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I-II trial of low-dose gemcitabine in prolonged infusion and cisplatin for advanced non-small cell lung cancer.
    Zwitter M; Kovac V; Smrdel U; Kocijancic I; Segedin B; Vrankar M
    Anticancer Drugs; 2005 Nov; 16(10):1129-34. PubMed ID: 16222156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
    Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
    Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II trial of weekly intravenous gemcitabine and cisplatin with continuous infusion fluorouracil in patients with metastatic renal cell carcinoma.
    George CM; Vogelzang NJ; Rini BI; Geoffroy FJ; Kollipara P; Stadler WM
    Ann Oncol; 2002 Jan; 13(1):116-20. PubMed ID: 11863091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of induction chemotherapy with gemcitabine and vinorelbine followed by concurrent chemoradiotherapy with oral etoposide and cisplatin in patients with inoperable stage III non-small-cell lung cancer.
    Lee DH; Han JY; Cho KH; Pyo HR; Kim HY; Yoon SJ; Lee JS
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1037-44. PubMed ID: 16024178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multicenter, randomized, Phase II study of cisplatin, etoposide, and gemcitabine or cisplatin plus gemcitabine as first-line treatment in patients with poor-prognosis small cell lung carcinoma.
    De Marinis F; Nelli F; Lombardo M; Ferraú F; Barbera S; Bertetto O; Barni S; Michetti G; Labianca R; Gridelli C
    Cancer; 2005 Feb; 103(4):772-9. PubMed ID: 15641037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.